Repotrectinib Patent Expiration
Repotrectinib is Used for treating locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adult patients. It was first introduced by Bristol Myers Squibb Co
Repotrectinib Patents
Given below is the list of patents protecting Repotrectinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Augtyro | US11452725 | Chiral diaryl macrocycles and uses thereof | Jul 24, 2036 | Bristol |
| Augtyro | US12310968 | Chiral diaryl macrocycles and uses thereof | Jul 20, 2036 | Bristol |
| Augtyro | US10294242 | Diaryl macrocycle polymorph | Jul 05, 2036 | Bristol |
| Augtyro | US12187739 | Diaryl macrocycle polymorph | Jul 05, 2036 | Bristol |
| Augtyro | US9714258 | Diaryl macrocycles as modulators of protein kinases | Jan 23, 2035 | Bristol |
| Augtyro | USRE50634 | Jan 23, 2035 | Bristol |
Repotrectinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Repotrectinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Turning Point Therapeutics, Inc. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis | MedSIR | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | Memorial Sloan Kettering Cancer Center | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants | Bristol-Myers Squibb | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |